Mycoplasma genitalium in Pregnancy
Azithromycin is the first-line treatment for Mycoplasma genitalium infection in pregnancy, but routine screening of asymptomatic pregnant women is not recommended.
Key Clinical Approach
When to Test
- Test only symptomatic pregnant patients presenting with cervicitis, urethritis, or pelvic inflammatory disease symptoms 1, 2
- Test sexual contacts of patients with confirmed M. genitalium infection 1
- Do NOT screen asymptomatic pregnant women without known exposure, even though multiplex PCR panels increasingly detect M. genitalium 3, 1
Diagnostic Strategy
- Use nucleic acid amplification testing (NAAT) - the only validated diagnostic method 2
- Ideally include macrolide resistance testing, though FDA-approved resistance tests are not widely available in the United States 1
- Testing should be focused to avoid inappropriate antibiotic use in pregnancy 1
Treatment Recommendations
First-Line Treatment (Macrolide-Susceptible or Unknown Resistance)
Azithromycin is universally recommended across all international guidelines for pregnancy 4, 5:
- Extended regimen (preferred): Azithromycin 500 mg on day 1, then 250 mg daily on days 2-5 2
- Alternative single-dose: Azithromycin 1 g orally as a single dose 4
The extended azithromycin regimen appears to have higher cure rates and may reduce selection of macrolide resistance 2.
Macrolide-Resistant Infections
This represents a critical gap in pregnancy management:
- Moxifloxacin is contraindicated in pregnancy - all guidelines advise against its use 4, 2
- Pristinamycin has been suggested by some European guidelines, but safety data in pregnancy are inconsistent and inconclusive 4
- Doxycycline is contraindicated in pregnancy (after first trimester due to tooth discoloration and bone effects) 6
Important Clinical Pitfalls
The multiplex PCR problem: The 75% surge in M. genitalium consultations after 2023 was driven largely by detection in asymptomatic pregnant patients through multiplex STI panels 3. This has led to:
- Unnecessary treatment with antibiotics in pregnancy
- Increased anxiety and clinical uncertainty
- Potential antimicrobial resistance pressure
Treatment failure concerns: 42% of M. genitalium consultations involve pregnancy management, and 35% involve treatment failures 3. This reflects:
- High rates of macrolide resistance (cure rates drop from 85-95% in susceptible infections to much lower with resistance) 2
- Limited safe treatment options in pregnancy
- Lack of resistance testing availability
Clinical Algorithm
Symptomatic pregnant patient (cervicitis, urethritis, PID symptoms):
- Test for M. genitalium with NAAT
- If positive → Treat with extended azithromycin regimen
- Request macrolide resistance testing if available
Asymptomatic pregnant patient with positive multiplex PCR:
- Assess for true exposure risk (sexual contact with known M. genitalium case)
- If no known exposure → Consider observation without treatment
- If known exposure → Treat with azithromycin
Treatment failure after azithromycin:
- Retest to confirm persistent infection
- Obtain macrolide resistance testing if not done initially
- If macrolide-resistant: No clearly safe alternative exists in pregnancy
- Consider infectious disease or STI specialist consultation 3
Evidence Quality and Gaps
The evidence base for M. genitalium management in pregnancy is notably weak:
- Only 4 international guidelines explicitly address pregnancy 4
- No randomized controlled trials of treatment in pregnancy exist 5
- Safety data for azithromycin is "generally reassuring" but based on observational studies 4
- The association with preterm birth and miscarriage is suggested but not definitively proven 5
Critical knowledge gap: There is no established safe and effective treatment for macrolide-resistant M. genitalium in pregnancy, creating a genuine therapeutic dilemma when azithromycin fails 4, 7.